Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors

DOI Web Site Web Site PubMed 被引用文献9件 参考文献36件
  • TABARA Yasuharu
    Department of Medical Genetics, Ehime University School of Medicine
  • TACHIBANA-IIMORI Rieko
    Department of Geriatric Medicine, Ehime University School of Medicine
  • KUSUHARA Hiroyuki
    Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • KOHARA Katsuhiko
    Department of Geriatric Medicine, Ehime University School of Medicine
  • NAKURA Jun
    Department of Geriatric Medicine, Ehime University School of Medicine
  • KAWAMOTO Ryuichi
    Department of Internal Medicine, Nomura Municipal Hospital
  • TOKUNAGA Katsushi
    Department of Human Genetics, Graduate School of Medicine, The University of Tokyo
  • KONDO Ikuko
    Department of Medical Genetics, Ehime University School of Medicine
  • SUGIYAMA Yuichi
    Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • MIKI Tetsuro
    Department of Geriatric Medicine, Ehime University School of Medicine

書誌事項

公開日
2004
資源種別
journal article
DOI
  • 10.2133/dmpk.19.375
公開者
日本薬物動態学会

この論文をさがす

説明

The effect of genetic polymorphism of human organic anion transporting polypeptide C (OATP-C) on the lipid-lowering response to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors was assessed.<br>    A retrospective study was conducted on 66 patients who underwent treatment of hyperlipidemia with HMG-CoA reductase inhibitors in a municipal hospital in a community-based cohort of Ehime prefecture in the southern part of Japan. Plasma lipid concentrations before and after administration were analyzed in patients in relation to the 521T/C (Val-174→Ala) polymorphism in the OATP-C gene (TT: n=44 (66.7%), TC: n=20 (30.3%), CC: n=0 (0.0%), undetermined: n=2 (3.0%)). Total cholesterol level was significantly lowered after treatment with HMG-CoA reductase inhibitors in all patients (p<0.001); moreover, subjects with the 521C allele showed an attenuated total-cholesterol-lowering effect compared with those homozygous for the 521T allele (-22.3±8.7% vs. -16.5±10.5%, p<0.05).<br>    These data suggest that the 521T/C polymorphism of the OATP-C gene modulates the lipid-lowering efficacy of HMG-CoA reductase inhibitors.<br>

収録刊行物

被引用文献 (9)*注記

もっと見る

参考文献 (36)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ